Recently, in a mouse model of ovarian cancer, the small-molecule CCR1 inhibitor UCB35625 demonstrated the ability to reduce cell migration to the greater omentum, a preferential metastatic site for such cancers (52). This evidence concerns the gene CCR1 and ovarian carcinoma.